Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of SHR6390 in Liver Impairment and Healthy Participants
NCT04631575Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of dalpiciclib in Hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from time zero to last measurable concentration and 1 more. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
Hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer
Beyond the preview
Go deeper on NCT04631575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631575.